Fortress Biotech, Inc. Lessee, Operating Lease, Liability, to be Paid
Fortress Biotech, Inc. (FBIO) had Lessee, Operating Lease, Liability, to be Paid of $16.03 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue · last filed 2026-08-13
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid $16.03M.
- 2026-03-31: Lessee, Operating Lease, Liability, to be Paid $16.78M.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid $17.56M.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid $17.87M.
| Period end | Lessee, Operating Lease, Liability, to be Paid |
|---|---|
| 2026-06-30 | $16.03M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $16.78M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $17.56M 10-K · filed 2026-03-31 |
| 2025-09-30 | $17.87M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $18.65M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $19.43M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $20.82M 10-K · filed 2025-03-31 |
| 2024-09-30 | $21.75M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $22.65M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $25.07M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $25.99M 10-K · filed 2024-03-28 |
| 2023-09-30 | $26.89M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $27.70M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $30.41M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $31.29M 10-K · filed 2023-03-31 |
| 2022-09-30 | $31.26M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $30.47M 10-K · filed 2022-03-28 |
| 2020-12-31 | $33.51M 10-K/A · filed 2021-04-09 |
| 2020-09-30 | $33.64M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $34.48M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $35.31M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $35.76M 10-K · filed 2020-03-16 |
| 2019-09-30 | $36.54M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $37.25M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $38.02M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |